Great Elm Group And 2 Other Stocks Under $2 Insiders Are Buying

Author: Avi Kapoor | March 01, 2024 07:56am

The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Great Elm Group

The Trade: Great Elm Group, Inc. (NASDAQ:GEG) 10% owner Imperial Capital Group Holdings II, LLC acquired a total of 124,090 shares an average price of $1.96. To acquire these shares, it cost around $238,539.
What’s Happening: On Feb. 13, Great Elm Group posted a loss for the second quarter.
What Great Elm Group Does: Great Elm Group Inc operates as a holding company. It focuses on growing a scalable and diversified portfolio of long-duration, permanent capital vehicles across corporate credit, specialty finance, real estate, and other asset classes.

Earth Science Tech

The Trade: Earth Science Tech, Inc. (OTC:ETST) CEO Giorgio R. Saumat acquired a total of 15,000 shares at at an average price of $0.08. To acquire these shares, it cost around $1,199.
What’s Happening: On Jan. 29, Earth Science Tech announced a $5 million common stock repurchase program.
What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company. Currently, the company is focused on emerging prospects in the health and wellness industry.

Check This Out: Dell, SoundHound AI And 3 Stocks To Watch Heading Into Friday

Emmaus Life Sciences

The Trade: Emmaus Life Sciences, Inc. (OTC:EMMA) Co-President and COO Willis C Lee acquired a total of 115,200 shares at an average price of $0.13. The insider spent around $14,694 to buy those shares.
What’s Happening: On Feb. 2, Emmaus Life Sciences received marketing authorization for Puerto Rico.
What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases.

Don’t forget to check out our premarket coverage here

Posted In: EMMA ETST GEG